Anti−PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1

INTRODUCTION: Novel anticancer therapies include anti–programmed cell death protein-1 (PD-1) and anti–programmed death ligand-1 (PD-L1) drugs. These novel medications have side effects in different organs, including the kidney. The most common adverse effect in the kidney is acute interstitial nephr...

Descripción completa

Detalles Bibliográficos
Autores principales: Cassol, Clarissa, Satoskar, Anjali, Lozanski, Gerard, Rovin, Brad, Hebert, Lee, Nadasdy, Tibor, Brodsky, Sergey V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Translational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698303/
https://www.ncbi.nlm.nih.gov/pubmed/31440705
http://dx.doi.org/10.1016/j.ekir.2019.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698303/
https://www.ncbi.nlm.nih.gov/pubmed/31440705
http://dx.doi.org/10.1016/j.ekir.2019.06.001

Ejemplares similares